Lopinavir/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: Week 104 analysis of AIDS clinical trials group (ACTG) A5230

by Kumarasamy N., Aga E., Ribaudo H., Wallis C., Katzenstein D., Stevens W., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Badal-Faesen S., Bartlett J.
Published 2015

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

by Bartlett J., Ribaudo H., Wallis C., Aga E., Katzenstein D., Stevens W., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Badal-Faesen S., Kallungal B., Kumarasamy N.
Published 2017

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phas...

by Tang M.W., Rhee S.-Y., Bertagnolio S., Ford N., Holmes S., Sigaloff K.C., Hamers R.L., De Wit T.F.R., Fleury H.J., Kanki P.J., Ruxrungtham K., Hawkins C.A., Wallis C.L., Stevens W., Van Zyl G.U., Manosuthi W., Hosseinipour M.C., Ngo-Giang-Huong N., Belec L., Peeters M., Aghokeng A., Bunupuradah T., Burda S., Cane P., Cappelli G., Charpentier C., Dagnra A.Y., Deshpande A.K., El-Katib Z., Eshleman S.H., Fokam J., Gody J.-C., Katzenstein D., Koyalta D.D., Kumwenda J.J., Lallemant M., Lynen L., Marconi V.C., Margot N.A., Moussa S., Ndung'U T., Nyambi P.N., Orrell C., Schapiro J.M., Schuurman R., Sirivichayakul S., Smith D., Zolfo M., Jordan M.R., Shafer R.W.
Published 2014